Search

Your search keyword '"Guerrero-Ramos F"' showing total 173 results
Start Over Author "Guerrero-Ramos F"
173 results on '"Guerrero-Ramos F"'

5. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

Author

Subiela, J.D., Gomis Sellés, E., Maldonado, A., Lopez Campos, F., Aumatell Ovide, J., Ajuria Illarramendi, O., González-Padilla, D.A., Gajate, P., Ortega Polledo, L.E., Alonso y Gregorio, S., Guerrero-Ramos, F., Gómez Dos Santos, V., Rodríguez-Patrón, R., Calais, J., Kishan, A.U., Burgos Revilla, F.J., and Couñago, F.

Published
2023
Full Text
View/download PDF

6. SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer

Author

Catto, J.W.F., primary, Necchi, A., additional, Powles, T., additional, Guerrero-Ramos, F., additional, Simone, G., additional, Shore, N., additional, Salinas, J.S., additional, Merseburger, A.S., additional, Roumiguie, M., additional, Hiroshi, K., additional, Morris, D.M., additional, Qiang, W., additional, Korkes, F., additional, Hasan, M., additional, Jin, S., additional, Maffeo, J., additional, Hammond, C., additional, Sweiti, H., additional, Somer, R.S., additional, and Chang, S.S., additional

Published
2024
Full Text
View/download PDF

7. First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients

Author

Guerrero-Ramos, F., primary, De Velasco, G., additional, Duenas, M., additional, Paramio, J., additional, García, V.M., additional, Gómez-Canizo, C., additional, Rodríguez-Izquierdo, M., additional, Hernández-Arroyo, M., additional, Martín-Torres, M.P., additional, Álvarez-Rodríguez, P., additional, Suárez, C., additional, Morales, L., additional, Ponce, S., additional, Rodríguez-Antolín, A., additional, and Castellano, D., additional

Published
2024
Full Text
View/download PDF

11. Analysis of referrals after a synergic work between primary care and urology. Impact of joint protocol implementation and a continuing education program in our healthcare area

Author

García-Rojo, E., Medina-Polo, J., Sopeña-Sutil, R., Guerrero-Ramos, F., García-Gómez, B., Aguilar-Gisbert, L., García-Álvarez, G., Azcutia-Gómez, M.R., Gómez-Martín, F., Molero-García, J.M., Pereda-Arregui, E., Vargas-Machuca Cabañero, M.C., Villacampa-Aubá, F., and Tejido Sánchez, Á.

Published
2019
Full Text
View/download PDF

12. Absence of Tumor (T0) on Second Transurethral Resection (ReTURB) Positively Impact Recurrence and Progression Risk Dynamics in a Contemporary Series of High-grade T1 Non-muscle Invasive Bladder Carcinoma Treated With Adequate Bacillus Calmette-Guérin

Author

Subiela Henriquez, J.D., primary, Krajewski, W., additional, Tukiendorf, A., additional, Aumatell, J, additional, González-Padilla, D., additional, Gomez-Rivas, J., additional, Gallioli, A., additional, Moschini, M., additional, Cimadamore, A., additional, D Andrea, D., additional, Mertens, L., additional, Alvarez-Maestro, M., additional, Pradere, B., additional, Marcq, G., additional, Afferi, L., additional, Basile, G., additional, Cano, J., additional, Guerrero-Ramos, F., additional, Lopez-Perez, E., additional, Montorsi, F., additional, Dominguez-Escrig, J.L., additional, Artiles-Medina, A., additional, Sanchez-Gonzalez, A., additional, Brasero-Burgos, J., additional, Yuen-Chun Teoh, J., additional, Rajwa, P., additional, Nowak, U., additional, Rodríguez-Faba, O., additional, Del Giudice, F., additional, Ploussard, G., additional, Tully, K., additional, Laukhtina, E., additional, Gomez-Dos Santos, V., additional, Szydelko, T., additional, Jimenez Cidre, M., additional, and Burgos Revilla, F.J., additional

Published
2023
Full Text
View/download PDF

13. Enhancing Predictions of the EAU21 Scoring Model in High-Grade Non-Muscle Invasive Bladder Carcinoma Treated with BCG using Explainable Machine Learning Survival Ensemble

Author

Subiela Henriquez, J.D., primary, Krajewski, W., additional, Aumatell, J.L., additional, González-Padilla, D., additional, Lopez, J., additional, Gomez-Rivas, J., additional, Gallioli, A., additional, Moschini, M., additional, Cimadamore, A., additional, D Andrea, D., additional, Mertens, L., additional, Alvarez-Maestro, M., additional, Pradere, B., additional, Marcq, G., additional, Afferi, L., additional, Basile, G., additional, Cano, J., additional, Guerrero-Ramos, F., additional, Lopez-Perez, E., additional, Montorsi, F., additional, Dominguez-Escrig, J.L., additional, Artiles-Medina, A., additional, Sanchez-Gonzalez, A., additional, Brasero-Burgos, J., additional, Yuen-Chun Teoh, J., additional, Rajwa, P., additional, Nowak, U., additional, Rodríguez-Faba, O., additional, Del Giudice, F., additional, Laukhtina, E., additional, Ploussard, G., additional, Tully, K., additional, Szydelko, T., additional, Gomez-Dos Santos, V., additional, Jimenez Cidre, M.A., additional, and Burgos Revilla, F.J., additional

Published
2023
Full Text
View/download PDF

17. LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4).

Author

Necchi, A., Guerrero-Ramos, F., Crispen, P.L., Herrera Imbroda, B., Garje, R., Powles, T.B., Peyton, C.C., Pradere, B., Ku, J.H., Shore, N.D., Boegemann, M., Preston, M.A., Xylinas, E., Gong, C., Najmi, S., Hasan, M., Stitou, H., Bhanvadia, S., Sweiti, H., and Psutka, S.P.

Subjects
*CANCER invasiveness, *NEOADJUVANT chemotherapy, *BLADDER cancer
Published
2024
Full Text
View/download PDF

19. LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)

Author

van der Heijden, M.S., Simone, G., Boegemann, M., Xylinas, E., Roumiguié, M., Guerrero-Ramos, F., Necchi, A., Daneshmand, S., Van Praet, C., Spiegelhalder, P., Decaestecker, K., Arentsen, H., Zainfeld, D., Hampras, S., Cutie, C.J., Sweiti, H., Stromberg, K., Martin, J., Shukla, A., and Jacob, J.M.

Published
2024
Full Text
View/download PDF

23. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.

Author

Tyson, Mark D., Morris, David, Palou, Juan, Rodriguez, Oscar, Mir, Maria Carmen, Dickstein, Rian J., Guerrero-Ramos, F(elix, Scarpato, Kristen R., Hafron, Jason M., Messing, Edward M., Cutie, Christopher J., Maffeo, John C., Raybold, Bradley, Chau, Albert, Stromberg, Katharine A., and Keegan, Kirk A.

Subjects
CANCER invasiveness, BLADDER cancer, UROTHELIUM, FRAIL elderly, OLDER patients, DRUG delivery systems
Abstract

Purpose: Half of patients with muscle-invasive bladder cancer worldwide may not receive curative-intent therapy. Elderly or frail patients are most affected by this unmet need. TAR-200 is a novel, intravesical drug delivery system that provides sustained, local release of gemcitabine into the bladder over a 21-day dosing cycle. The phase 1 TAR-200-103 study evaluated the safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who either refused or were unfit for curative-intent therapy. Materials and Methods: Eligible patients had cT2-cT3bN0M0 urothelial carcinoma of the bladder. TAR-200 was inserted for 4 consecutive 21-day cycles over [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Long-term prospective results of the Spanish multicentre experience using recirculant hyperthermic MMC with Combat BRS HIVEC system

Author

Guerrero-Ramos, F., primary, Plata-Bello, A., additional, González-Díaz, A., additional, García, C., additional, González-Valcárcel, I., additional, De La Morena-Gallego, J.M., additional, Díaz-Goizueta, F.J., additional, Fernández-Álamo, J., additional, Gonzalo, V., additional, Montero, J., additional, Sousa-Escandón, A., additional, León, J., additional, Pontones, J.L., additional, Delgado, F., additional, Adriazola, M., additional, Pascual, Á., additional, Calleja, J., additional, Ruano, A., additional, Martínez-Piñeiro, L., additional, and Angulo-Cuesta, J., additional

Published
2022
Full Text
View/download PDF

25. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Author

Zhao, H, primary, Chan, V W S, additional, Castellani, D, additional, Chan, E O T, additional, Ong, W L K, additional, Peng, Q, additional, Moschini, M, additional, Krajewski, W, additional, Pradere, B, additional, Ng, C F, additional, Enikeev, D, additional, Vasdev, N, additional, Ekin, G, additional, Sousa, A, additional, Leon, J, additional, Guerrero-Ramos, F, additional, Tan, W S, additional, Kelly, J, additional, Shariat, S F, additional, Witjes, J A, additional, and Teoh, J Y C, additional

Published
2021
Full Text
View/download PDF

26. 676P CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)

Author

De Velasco, G., primary, Alonso-Gordoa, T., additional, Rodríguez-Moreno, J.F., additional, Duran, I., additional, Carretero-González, A., additional, Martin-Soberon, M., additional, Gutiérrez Baños, J.L., additional, Guerrero-Ramos, F., additional, Dueñas, M., additional, and Castellano Gauna, D., additional

Published
2021
Full Text
View/download PDF

27. Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis

Author

Zhao, H., primary, Chan, V.W., additional, Castellani, D., additional, Chan, E.O., additional, Ong, W.L.K., additional, Peng, Q., additional, Moschini, M., additional, Krajewski, W., additional, Pradere, B., additional, Ng, C., additional, Enikeev, D., additional, Vasdev, N., additional, Ekin, G., additional, Sousa, A., additional, Leon, J., additional, Guerrero-Ramos, F., additional, Tan, W., additional, Kelly, J., additional, Shariat, S.F., additional, Witjes, J., additional, and Teoh, J.Y.., additional

Published
2021
Full Text
View/download PDF

28. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)

Author

Alvarez-Maestro, M, Guerrero-Ramos, F, Rodriguez-Faba, O, Dominguez-Escrig, JL, and Fernandez-Gomez, JM

Subjects
BGG failure, Current treatments, Immunotherapy, Non-muscle invasive bladder cancer, Intravesical chemotherapy
Abstract

The treatment of choice for high-risk non-muscle invasive bladder cancer (NMIBC) is bacillus Calmette-Guerin (BCG). However, when this fails, the indicated treatment is radical cystectomy. In recent years, trials are being developed with various drugs to avoid this surgery in patients with BCG failure. The aim of this article is to update the treatments under study for bladder preservation in this patient population. Non-systematic review, searching PubMed with the terms "Bladder cancer", "Non-muscle invasive bladder cancer", "NMIBC", "BCG", "BCG-refractory", "Mitomycin C", "MMC", "Hyperthermia", "Electromotive Drug Administration", "EMDA". We used the search engines clinicaltrials.gov and clinicaltrialsregister.eu to find clinical trials. The only intravesical drug approved by the Food and Drug Administration (FDA) for carcinoma in situ (CIS) after failure to BCG is Valrubicin. Recently, the FDA has approved intravenous Pembrolizumab, following the publication of preliminary data from the KEYNOTE-057 study. Atezolizumab has demonstrated similar preliminary efficacy results. Only microwave-induced chemohyperthermia and EMDA-MMC (Electromotive Drug Administration) are recognized as alternatives in European guidelines. Other options under investigation are taxanes and gemcitabine, alone or in combination, recombinant viruses and device-assisted intravesical chemohyperthermia. The results of new drugs are promising, with a large number of trials underway. Knowing the mechanisms of resistance to BCG is essential to explore new therapeutic options. (C) 2020 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.

Published
2021

29. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain

Author

Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, Díaz-Goizueta FJ, Del Álamo JF, Gonzalo V, Montero J, Sousa-Escandón A, León J, Pontones JL, Delgado F, Adriazola M, Pascual Á, Calleja J, Ruano A, Martínez-Piñeiro L, and Angulo JC

Subjects
bladder neoplasia, bladder recirculation system, hyperthermic intravesical chemotherapy, mitomycin-C
Abstract

(1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context of a relative BCG shortage. We aim to determine real-world data on the long-term treatment outcomes of adjunct hyperthermic intravesical chemotherapy (HIVEC) with MMC and a COMBAT® bladder recirculation system (BRS); (2) Methods: A prospective observational trial was performed on patients with NMIBC treated with HIVEC using BRS in nine academic institutions in Spain between 2012-2020 (HIVEC-E). Treatment effectiveness (recurrence, progression and overall mortality) was evaluated in patients treated with HIVEC MMC 40mg in the adjuvant setting, with baseline data and a clinical follow-up, that comprise the Full Analysis Set (FAS). Safety, according to the number and severity of adverse effects (AEs), was evaluated in the safety (SAF) population, composed by patients with at least one adjunct HIVEC MMC instillation; (3) Results: The FAS population ( n = 502) received a median number of 8.78 ± 3.28 (range 1-20) HIVEC MMC instillations. The median follow-up duration was 24.5 ± 16.5 (range 1-81) months. Its distribution, based on EAU risk stratification, was 297 (59.2%) for intermediate and 205 (40.8%) for high-risk. The figures for five-year recurrence-free and progression-free survival were 50.37% (53.3% for intermediate and 47.14% for high-risk) and 89.83% (94.02% for intermediate and 84.23% for high-risk), respectively. A multivariate analysis identified recurrent tumors (HR 1.83), the duration of adjuvant HIVEC therapy

Published
2021

30. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Author

Zhao, H, Chan, V.W., Castellani, D., Chan, E.O., Ong, W.L.K., Peng, Q., Moschini, M., Krajewski, W., Pradere, B., Ng, C.F., Enikeev, D., Vasdev, N., Ekin, G., Sousa, A., Leon, J. de, Guerrero-Ramos, F., Tan, W.S., Kelly, J., Shariat, S.F., Witjes, J.A., Teoh, J.Y., Zhao, H, Chan, V.W., Castellani, D., Chan, E.O., Ong, W.L.K., Peng, Q., Moschini, M., Krajewski, W., Pradere, B., Ng, C.F., Enikeev, D., Vasdev, N., Ekin, G., Sousa, A., Leon, J. de, Guerrero-Ramos, F., Tan, W.S., Kelly, J., Shariat, S.F., Witjes, J.A., and Teoh, J.Y.

Abstract

Contains fulltext : 244254.pdf (Publisher’s version ) (Open Access), Background: The efficacy of intravesical chemotherapy maintenance for patients with non-muscle invasive bladder cancer (NMIBC) is inferior compared to intravesical bacillus Calmette-Guerin (BCG). How intravesical chemohyperthermia (CHT) compares with BCG is under investigation. Objective: To compare the oncological outcomes and safety profile between intravesical CHT and BCG treatment for intermediate- and high-risk NMIBC. Methods: We performed a systematic review and meta-analysis of clinical studies comparing CHT with BCG for intermediate- and high-risk NMIBC patients. A comprehensive literature search on OVID MEDLINE, EMBASE, and Cochrane Library was conducted. Risk of bias was assessed by the Cochrane RoB tool and ROBINS-I. Certainty of evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Results: A total of 2,375 articles were identified and five studies were finally included. Among them, four randomised trials comprising 327 patients (CHT group: 156 patients; BCG group: 171 patients) were included in the meta-analysis. There were no significant differences in the 24-36 months recurrence rates (CHT: 29.5%, BCG: 37.4%; RR: 0.83, 95% CI 0.61-1.13; moderate certainty of evidence) and the 24-36 months progression rates (CHT: 4.4%, BCG: 7.6%, RR = 0.62, 95% CI 0.26-1.49; low certainty of evidence). There were also no significant differences in grade 1-2 adverse events (CHT group: 59.9%, BCG group 54.5%; RR = 1.10, 95% CI 0.93-1.30; moderate certainty of evidence) and grade 3 or above adverse events (CHT group: 23.2%, BCG group 22.5%; RR = 0.99, 95% CI 0.69-1.43; low certainty of evidence). Conclusions: Intravesical CHT had equivalent oncological outcomes and similar safety profile when compared to BCG maintenance therapy for patients with intermediate- and high-risk NMIBC. CHT is a possible alternative treatment in the times of BCG shortage.

Published
2021

31. P259 - Enhancing Predictions of the EAU21 Scoring Model in High-Grade Non-Muscle Invasive Bladder Carcinoma Treated with BCG using Explainable Machine Learning Survival Ensemble

Author

Subiela Henriquez, J.D., Krajewski, W., Aumatell, J.L., González-Padilla, D., Lopez, J., Gomez-Rivas, J., Gallioli, A., Moschini, M., Cimadamore, A., D Andrea, D., Mertens, L., Alvarez-Maestro, M., Pradere, B., Marcq, G., Afferi, L., Basile, G., Cano, J., Guerrero-Ramos, F., Lopez-Perez, E., Montorsi, F., Dominguez-Escrig, J.L., Artiles-Medina, A., Sanchez-Gonzalez, A., Brasero-Burgos, J., Yuen-Chun Teoh, J., Rajwa, P., Nowak, U., Rodríguez-Faba, O., Del Giudice, F., Laukhtina, E., Ploussard, G., Tully, K., Szydelko, T., Gomez-Dos Santos, V., Jimenez Cidre, M.A., and Burgos Revilla, F.J.

Published
2023
Full Text
View/download PDF

32. P260 - Absence of Tumor (T0) on Second Transurethral Resection (ReTURB) Positively Impact Recurrence and Progression Risk Dynamics in a Contemporary Series of High-grade T1 Non-muscle Invasive Bladder Carcinoma Treated With Adequate Bacillus Calmette-Guérin

Author

Subiela Henriquez, J.D., Krajewski, W., Tukiendorf, A., Aumatell, J, González-Padilla, D., Gomez-Rivas, J., Gallioli, A., Moschini, M., Cimadamore, A., D Andrea, D., Mertens, L., Alvarez-Maestro, M., Pradere, B., Marcq, G., Afferi, L., Basile, G., Cano, J., Guerrero-Ramos, F., Lopez-Perez, E., Montorsi, F., Dominguez-Escrig, J.L., Artiles-Medina, A., Sanchez-Gonzalez, A., Brasero-Burgos, J., Yuen-Chun Teoh, J., Rajwa, P., Nowak, U., Rodríguez-Faba, O., Del Giudice, F., Ploussard, G., Tully, K., Laukhtina, E., Gomez-Dos Santos, V., Szydelko, T., Jimenez Cidre, M., and Burgos Revilla, F.J.

Published
2023
Full Text
View/download PDF

33. LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)

Author

Vilaseca, A., Jayram, G., Raventos, C., Shore, N.D., Zainfeld, D., Kang, T.W., Ku, J.H., Meeks, J., Rodríguez Faba, Ó., Roghmann, F., Daneshmand, S., Beeharry, N., Cost, C., Kalota, A., Lauring, J., Peterson, M., Quiroz, M., Stone, N., Zhu, W., and Guerrero-Ramos, F.

Published
2023
Full Text
View/download PDF

34. 2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)

Author

Necchi, A., Catto, J.W.F., Powles, T.B., Guerrero-Ramos, F., Simone, G., Shore, N.D., Salinas, J., Merseburger, A.S., Roumiguié, M., Kitamura, H., Morris, D., Wei, Q., Korkes, F., Hasan, M., Jin, S., Maffeo, J., Hammond, C., Sweiti, H., Somer, R., and Chang, S.S.

Published
2023
Full Text
View/download PDF

37. Carcinoma in situ of the bladder: why is it underdetected?

Author

Subiela, JD, Rodriguez Faba, O, Guerrero-Ramos, F, Aumatell, J, Breda, A, and Palou, J

Subjects
immune checkpoint inhibitors, bladder cancer, carcinoma in situ, narrow band imaging, Bacillus Calmette-Guerin, photodynamic diagnosis
Abstract

Purpose of review The standard diagnosis of carcinoma in situ (CIS) of the bladder, based on white light cystoscopy and urine cytology, is limited because CIS can vary from normal-appearing mucosa to a lesion indistinguishable from an inflammatory process. Intravesical instillation of Bacillus Calmette-Guerin (BCG) remains first-line therapy; however, a significant proportion of cases persist or recur after BCG treatment. This review summarizes recent improvements in the detection and treatment of CIS. Recent findings The new optical technologies improve CIS detection, with a potential positive impact on oncological outcomes. The usefulness of MRI-photodynamic diagnosis fusion transurethral resection in CIS detection is unclear and further studies are needed. BCG instillation remains the first-line therapy in CIS patients and seems to improve recurrence and progression rates, especially with the use of maintenance. Intravesical device-assisted therapies could be effective in both BCG-naive and BCG-unresponsive CIS patients, but further studies are ongoing to clarify their clinical benefit. A phase II clinical trial with pembrolizumab has shown the potential effectiveness of immune checkpoint inhibitors in BCG-unresponsive CIS patients and further trials are ongoing. Summary New optical techniques increase the CIS detection rate. BCG instillation remains the first-line treatment. Immune checkpoint inhibitors could be a future alternative in BCG-naive and BCG-unresponsive CIS patients.

Published
2020

39. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future

Author

Rey-Cárdenas, M., primary, Guerrero-Ramos, F., additional, Gómez de Liaño Lista, A., additional, Carretero-González, A., additional, Bote, H., additional, Herrera-Juárez, M., additional, Carril-Ajuria, L., additional, Martín-Soberón, M., additional, Sepulveda, J.M., additional, Billalabeitia, E.G., additional, Castellano, D., additional, and de Velasco, G., additional

Published
2021
Full Text
View/download PDF

42. A0731 - First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients.

Author

Guerrero-Ramos, F., De Velasco, G., Duenas, M., Paramio, J., García, V.M., Gómez-Canizo, C., Rodríguez-Izquierdo, M., Hernández-Arroyo, M., Martín-Torres, M.P., Álvarez-Rodríguez, P., Suárez, C., Morales, L., Ponce, S., Rodríguez-Antolín, A., and Castellano, D.

Subjects
*NON-muscle invasive bladder cancer, *BCG immunotherapy, *ATEZOLIZUMAB, *CANCER patients, *CLINICAL trials
Published
2024
Full Text
View/download PDF

43. Evolución de las derivaciones desde Atención Primaria a Urología tras la creación de un grupo de trabajo y la instauración de protocolos y cursos de formación continuada

Author

García-Rojo, E., primary, Medina-Polo, J., additional, Sopeña-Sutil, R., additional, Guerrero-Ramos, F., additional, García-Gómez, B., additional, Aguilar-Gisbert, L., additional, García-Álvarez, G., additional, Azcutia-Gómez, M.R., additional, Gómez-Martín, F., additional, Molero-García, J.M., additional, Pereda-Arregui, E., additional, Vargas-Machuca Cabañero, M.C., additional, Villacampa-Aubá, F., additional, and Tejido Sánchez, Á., additional

Published
2019
Full Text
View/download PDF

45. Anti-CD20 and mTOR inhibitors: Can we change the prognosis of post-transplant lymphoproliferative disorder?

Author

Guerrero Ramos, F., primary, Cavero Escribano, T., additional, Pamplona Casamayor, M., additional, Rodriguez Antolín, A., additional, Duarte Ojeda, J., additional, Tejido Sánchez, Á., additional, Villacampa Aubá, F., additional, Medina Polo, J., additional, González Monte, E., additional, Passas Martínez, J., additional, and De La Rosa Kehrmann, F., additional

Published
2018
Full Text
View/download PDF

46. La survie des transplantations rénales des donneurs à cœur non battant incontrôlés sous la protection normothermique : sont-ils aussi bons que les reins des donneurs à cœur battant ?

Author

Guerrero-Ramos, F., primary, Cavero-Escribano, T., additional, De la Rosa-Kehrmann, F., additional, Rodríguez-Antolín, A., additional, Pamplona-Casamayor, M., additional, Duarte-Ojeda, J., additional, Tejido-Sánchez, Á., additional, Villacampa-Aubá, F., additional, Medina-Polo, J., additional, Andrés-Belmonte, A., additional, and Passas-Martínez, J., additional

Published
2017
Full Text
View/download PDF

49. Kidney transplantation from uncontrolled donation after circulatory death (IIa): Organ procurement and renal harvested over a ten year period

Author

Medina Polo, J., primary, Justo-Quintas, J., additional, Gil-Moradillo, J., additional, De La Rosa-Kehrmann, F., additional, Pamplona-Casamayor, M., additional, Rodríguez-Antolín, A., additional, Duarte-Ojeda, J.M., additional, Tejido-Sánchez, A., additional, Villacampa-Aubá, F., additional, Sopeña-Sutil, R., additional, Benitez-Sala, R., additional, Guerrero-Ramos, F., additional, Andrés-Belmonte, A., additional, and Passas-Martínez, J.B., additional

Published
2017
Full Text
View/download PDF

50. Documento de consenso sobre las implicaciones de la normalización del suministro del BCG en el manejo del paciente con tumor vesical no-músculo invasivo (TVNMI)

Author

Rodríguez Faba, Ó., Fernández Gómez, J.M., Guerrero-Ramos, F., Álvarez-Maestro, M., Ledo Cepero, M.J., Unda Urzaiz, M., Martínez-Piñeiro, L., Cózar Olmo, J.M., Palou Redorta, J., and Álvarez-Ossorio, J.L.

Abstract

Los pacientes con tumor vesical no-músculo invasivo (TVNMI) de los grupos de riesgo intermedio y alto deben ser tratados con el bacilo de Calmette-Guérin (BCG) intravesical adyuvante después de la resección transuretral (RTU), ya que dicho tratamiento disminuye el riesgo de recurrencia y, probablemente también, el de progresión. La optimización de la eficacia del BCG se consigue administrando un tratamiento de mantenimiento. Sin embargo, dado que se desconocen muchos detalles inmunológicos del mecanismo de acción del BCG en la vejiga, la implementación a lo largo de las últimas décadas de la dosis óptima, número de instilaciones, cepas y régimen adecuado de mantenimiento, se ha realizado de manera heterogénea, lo que ha generado dificultades para interpretar los resultados de eficacia oncológica. Esto unido con el desabastecimiento del BCG que se ha sufrido en los últimos años, ha hecho que las diferentes sociedades científicas tengan que adaptar sus guías de práctica clínica a esta situación, modificando durante este tiempo sus protocolos de tratamiento adyuvante con el BCG con relación a las cepas, a la dosis y al mantenimiento. En este documento de consenso, se evalúa el estado actual del tratamiento adyuvante con el BCG y las implicaciones de la normalización del suministro del BCG en el tratamiento oncológico de los pacientes con TVNMI, así como la implementación de nuevos tratamientos que en el futuro mejoren el pronóstico oncológico y la calidad de vida de los pacientes con TVNMI.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results